Compare Enact Holdings Inc (ACT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enact Holdings Inc vs TG Therapeutics Inc — how do they compare? Enact Holdings Inc trades at $49.44 (market cap $6.75B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Enact Holdings Inc and TG Therapeutics Inc are close in size by market cap, and Enact Holdings Inc pays a 1.95% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ACT | TGTX | |
|---|---|---|
Market Cap | $6.75B | $7.64B |
Sector | Technology | Health |
52-Week High | $49.12 | $59.06 |
52-Week Low | $34.93 | $26.94 |
Enterprise Value | $7.05B | $7.84B |
Dividend Yield | 1.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACT trades at $49.54, up 2.14% today, near the consensus price target of $49.00. The stock shows strong profitability with a net income margin of 54.51% and a P/E ratio of 10.36, indicating potential undervaluation. Recent Q2 2026 earnings beat estimates at $1.26 per share. Technical indicators signal a bullish trend, though RSI levels suggest overbought conditions. The company maintains stable dividends, with a $0.24 payout scheduled for September 2026.
Outlook is cautiously optimistic with solid fundamentals and analyst support, but risks include reliance on steady earnings growth and market volatility. The stock offers value with room for upside if earnings momentum continues, though overbought technicals may prompt short-term consolidation.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enact Holdings Inc
Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.
Read more on ACT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
